Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
4.960
-0.070 (-1.39%)
Dec 3, 2024, 11:38 AM EST - Market open
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2024, Kazia Therapeutics had annual revenue of 2.48M AUD with 248,000.00% growth. Kazia Therapeutics had revenue of 2.48M in the half year ending June 30, 2024.
Revenue (ttm)
2.48M AUD
Revenue Growth
+248,000.00%
P/S Ratio
7.96
Revenue / Employee
275,667 AUD
Employees
9
Market Cap
21.60M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% |
Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% |
Jun 30, 2022 | 10.00K | -15.17M | -99.93% |
Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% |
Jun 30, 2020 | 988.11K | -451.89K | -31.38% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Concord Medical Services Holdings | 64.91M |
Flora Growth | 64.15M |
Spruce Biosciences | 7.10M |
NEXGEL | 6.73M |
Palatin Technologies | 2.38M |
GlycoMimetics | 10.00K |
KZIA News
- 4 weeks ago - Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - PRNewsWire
- 2 months ago - Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting - PRNewsWire
- 2 months ago - Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium - PRNewsWire
- 2 months ago - KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - PRNewsWire
- 5 months ago - Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment - Benzinga
- 5 months ago - Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma - PRNewsWire
- 5 months ago - KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER - PRNewsWire
- 6 months ago - Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - PRNewsWire